Aromatase inhibitors, such as letrozole, however, have been shown to have superior efficacy to tamoxifen in both early and advanced breast cancer with response rates of 30%–50% as first-line metastatic therapy [6]. This evidence concerns the gene CYP19A1 and breast cancer.